Assessing the circulating placental-specific anti-angiogenic protein sFLT-1 e15a in preeclampsia

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Other

Abstract

Preeclampsia is a common obstetric complication globally responsible for a significant burden of maternal and perinatal morbidity and mortality. The anti-angiogenic protein, sFLT-1, plays a central role in its pathophysiology. sFLT-1 is released from a range of tissues into the circulation, where it antagonizes the activity of vascular endothelial growth factor and placental growth factor leading to endothelial dysfunction. The resulting widespread endothelial dysfunction produces the clinical features of preeclampsia including hypertension and proteinuria. Multiple splice variants of sFLT-1 have been identified, with one, known as sFLT-1 e15a, present only in humans and higher-order primates. This sFLT-1 variant is also the main form of sFLT-1 produced by the placenta. Recent work has shown that sFLT-1 e15a is significantly elevated in the placenta and circulation of women with preeclampsia. It is also biologically active, capable of causing endothelial dysfunction and end-organ dysfunction seen in preeclampsia. Indeed, overexpression of sFLT-1 e15a in mice recapitulates the preeclamptic phenotype in pregnancy. No commercial assay currently exists to analyze sFLT-1 e15a protein levels. Here, a new ELISA method to determine circulating sFLT-1 variant levels is described.

Original languageEnglish
Title of host publicationPreeclampsia: Methods and Protocols
Subtitle of host publicationMethods in Molecular Biology
EditorsPadma Murthi, Cathy Vaillancourt
Place of PublicationNY USA
PublisherHumana Press
Chapter3
Pages27-37
Number of pages11
ISBN (Print)978-1-4939-7497-9
DOIs
Publication statusPublished - 1 Jan 2018

Publication series

NameMethods in Molecular Biology
Volume1710
ISSN (Print)1064-3745

Keywords

  • ELISA
  • Immunoassay
  • Preeclampsia
  • Protein
  • sFLT-1
  • Splice variant

Cite this

Palmer, K. R. (2018). Assessing the circulating placental-specific anti-angiogenic protein sFLT-1 e15a in preeclampsia. In P. Murthi, & C. Vaillancourt (Eds.), Preeclampsia: Methods and Protocols: Methods in Molecular Biology (pp. 27-37). (Methods in Molecular Biology; Vol. 1710). NY USA: Humana Press. https://doi.org/10.1007/978-1-4939-7498-6_3
Palmer, Kirsten Rebecca. / Assessing the circulating placental-specific anti-angiogenic protein sFLT-1 e15a in preeclampsia. Preeclampsia: Methods and Protocols: Methods in Molecular Biology. editor / Padma Murthi ; Cathy Vaillancourt. NY USA : Humana Press, 2018. pp. 27-37 (Methods in Molecular Biology).
@inbook{98273bebb7f041a0b9a1ee6c74559f49,
title = "Assessing the circulating placental-specific anti-angiogenic protein sFLT-1 e15a in preeclampsia",
abstract = "Preeclampsia is a common obstetric complication globally responsible for a significant burden of maternal and perinatal morbidity and mortality. The anti-angiogenic protein, sFLT-1, plays a central role in its pathophysiology. sFLT-1 is released from a range of tissues into the circulation, where it antagonizes the activity of vascular endothelial growth factor and placental growth factor leading to endothelial dysfunction. The resulting widespread endothelial dysfunction produces the clinical features of preeclampsia including hypertension and proteinuria. Multiple splice variants of sFLT-1 have been identified, with one, known as sFLT-1 e15a, present only in humans and higher-order primates. This sFLT-1 variant is also the main form of sFLT-1 produced by the placenta. Recent work has shown that sFLT-1 e15a is significantly elevated in the placenta and circulation of women with preeclampsia. It is also biologically active, capable of causing endothelial dysfunction and end-organ dysfunction seen in preeclampsia. Indeed, overexpression of sFLT-1 e15a in mice recapitulates the preeclamptic phenotype in pregnancy. No commercial assay currently exists to analyze sFLT-1 e15a protein levels. Here, a new ELISA method to determine circulating sFLT-1 variant levels is described.",
keywords = "ELISA, Immunoassay, Preeclampsia, Protein, sFLT-1, Splice variant",
author = "Palmer, {Kirsten Rebecca}",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/978-1-4939-7498-6_3",
language = "English",
isbn = "978-1-4939-7497-9",
series = "Methods in Molecular Biology",
publisher = "Humana Press",
pages = "27--37",
editor = "Padma Murthi and Cathy Vaillancourt",
booktitle = "Preeclampsia: Methods and Protocols",
address = "United States of America",

}

Palmer, KR 2018, Assessing the circulating placental-specific anti-angiogenic protein sFLT-1 e15a in preeclampsia. in P Murthi & C Vaillancourt (eds), Preeclampsia: Methods and Protocols: Methods in Molecular Biology. Methods in Molecular Biology, vol. 1710, Humana Press, NY USA, pp. 27-37. https://doi.org/10.1007/978-1-4939-7498-6_3

Assessing the circulating placental-specific anti-angiogenic protein sFLT-1 e15a in preeclampsia. / Palmer, Kirsten Rebecca.

Preeclampsia: Methods and Protocols: Methods in Molecular Biology. ed. / Padma Murthi; Cathy Vaillancourt. NY USA : Humana Press, 2018. p. 27-37 (Methods in Molecular Biology; Vol. 1710).

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Other

TY - CHAP

T1 - Assessing the circulating placental-specific anti-angiogenic protein sFLT-1 e15a in preeclampsia

AU - Palmer, Kirsten Rebecca

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Preeclampsia is a common obstetric complication globally responsible for a significant burden of maternal and perinatal morbidity and mortality. The anti-angiogenic protein, sFLT-1, plays a central role in its pathophysiology. sFLT-1 is released from a range of tissues into the circulation, where it antagonizes the activity of vascular endothelial growth factor and placental growth factor leading to endothelial dysfunction. The resulting widespread endothelial dysfunction produces the clinical features of preeclampsia including hypertension and proteinuria. Multiple splice variants of sFLT-1 have been identified, with one, known as sFLT-1 e15a, present only in humans and higher-order primates. This sFLT-1 variant is also the main form of sFLT-1 produced by the placenta. Recent work has shown that sFLT-1 e15a is significantly elevated in the placenta and circulation of women with preeclampsia. It is also biologically active, capable of causing endothelial dysfunction and end-organ dysfunction seen in preeclampsia. Indeed, overexpression of sFLT-1 e15a in mice recapitulates the preeclamptic phenotype in pregnancy. No commercial assay currently exists to analyze sFLT-1 e15a protein levels. Here, a new ELISA method to determine circulating sFLT-1 variant levels is described.

AB - Preeclampsia is a common obstetric complication globally responsible for a significant burden of maternal and perinatal morbidity and mortality. The anti-angiogenic protein, sFLT-1, plays a central role in its pathophysiology. sFLT-1 is released from a range of tissues into the circulation, where it antagonizes the activity of vascular endothelial growth factor and placental growth factor leading to endothelial dysfunction. The resulting widespread endothelial dysfunction produces the clinical features of preeclampsia including hypertension and proteinuria. Multiple splice variants of sFLT-1 have been identified, with one, known as sFLT-1 e15a, present only in humans and higher-order primates. This sFLT-1 variant is also the main form of sFLT-1 produced by the placenta. Recent work has shown that sFLT-1 e15a is significantly elevated in the placenta and circulation of women with preeclampsia. It is also biologically active, capable of causing endothelial dysfunction and end-organ dysfunction seen in preeclampsia. Indeed, overexpression of sFLT-1 e15a in mice recapitulates the preeclamptic phenotype in pregnancy. No commercial assay currently exists to analyze sFLT-1 e15a protein levels. Here, a new ELISA method to determine circulating sFLT-1 variant levels is described.

KW - ELISA

KW - Immunoassay

KW - Preeclampsia

KW - Protein

KW - sFLT-1

KW - Splice variant

UR - http://www.scopus.com/inward/record.url?scp=85037039440&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-7498-6_3

DO - 10.1007/978-1-4939-7498-6_3

M3 - Chapter (Book)

SN - 978-1-4939-7497-9

T3 - Methods in Molecular Biology

SP - 27

EP - 37

BT - Preeclampsia: Methods and Protocols

A2 - Murthi, Padma

A2 - Vaillancourt, Cathy

PB - Humana Press

CY - NY USA

ER -

Palmer KR. Assessing the circulating placental-specific anti-angiogenic protein sFLT-1 e15a in preeclampsia. In Murthi P, Vaillancourt C, editors, Preeclampsia: Methods and Protocols: Methods in Molecular Biology. NY USA: Humana Press. 2018. p. 27-37. (Methods in Molecular Biology). https://doi.org/10.1007/978-1-4939-7498-6_3